The integrated stress response (ISR) is an adaptive pathway hijacked by cancer cells to survive cellular stresses in the tumor microenvironment. ISR activation potently induces PD-L1, leading to suppression of antitumor immunity. In this study, we sought to uncover additional immune checkpoint proteins regulated by the ISR to elucidate mechanisms of tumor immune escape. The ISR coordinately induced cluster of differentiation 155 (CD155) and PD-L1, enhancing translation of both immune checkpoint proteins through bypass of inhibitory upstream open reading frames in their 5′ untranslated regions. Analysis of primary human lung tumors identified a significant correlation between expression of PD-L1 and CD155. ISR activation accelerated tumorigenesis and inhibited T-cell function, which could be overcome by combining PD-1 and TIGIT blockade with the ISR inhibitor ISRIB. This study uncovers a mechanism by which two immune checkpoint proteins are coordinately regulated and suggests a therapeutic strategy for patients with lung cancer. Significance: The integrated stress response represents a targetable axis to improve the efficacy of immunotherapy in lung cancer by inhibiting the coordinated translational regulation of the PD-L1/PD-1 and CD155/TIGIT immune checkpoint pathways.
15 October 2018 in Journal of Cellular Biochemistry
Background: Breast (BCa) and prostate (PCa) cancers are hormone receptor (HR)-driven cancers. Thus, BCa and PCa patients are given therapies that reduce hormone levels or directly block HR activity; but most patients eventually develop treatment resistance. We have previously reported that interleukin-1 (IL-1) inflammatory cytokine downregulatesERαandARmRNA in HR-positive (HR+) BCa and PCa cell lines, yet the cells can remain viable. Additionally, we identified pro-survival proteins and processes upregulated by IL-1 in HR+BCa and PCa cells, that are basally high in HR−BCa and PCa cells. Therefore, we hypothesize that IL-1 confers a conserved gene expression pattern in HR+BCa and PCa cells that mimics conserved basal gene expression patterns in HR−BCa and PCa cells to promote HR-independent survival and tumorigenicity.Methods: We performed RNA sequencing (RNA-seq) for HR+BCa and PCa cell lines exposed to IL-1 and for untreated HR−BCa and PCa cell lines. We confirmed expression patterns of select genes by RT-qPCR and used siRNA and/or drug inhibition to silence select genes in the BCa and PCa cell lines. Finally, we performed Ingenuity Pathway Analysis (IPA) and used the gene ontology web-based tool, GOrilla, to identify signaling pathways encoded by our RNA-seq data set.Results: We identified 350 genes in common between BCa and PCa cells that are induced or repressed by IL-1 in HR+cells that are, respectively, basally high or low in HR−cells. Among these genes, we identifiedSequestome-1(SQSTM1/p62) andSRY(Sex-Determining Region Y)-Box 9(SOX9) to be essential for survival of HR−BCa and PCa cell lines. Analysis of publicly available data indicates thatp62andSOX9expression are elevated in HR-independent BCa and PCa sublines generated in vitro, suggesting thatp62andSOX9have a role in acquired hormone receptor independence and treatment resistance. We also assessed HR−cell line viability in response to the p62-targeting drug, verteporfin, and found that verteporfin is cytotoxic for HR−cell lines.Conclusions: Our 350 gene set can be used to identify novel therapeutic targets and/or biomarkers conserved among acquired (e.g. due to inflammation) or intrinsic HR-independent BCa and PCa.